Syneos Health Inc – Class A (NASDAQ:SYNH) Short Interest Reduced By 3.23%

November 10, 2018 - By Joe Cepeda

It was registered a decrease on Syneos Health Inc – Class A (NASDAQ:SYNH)’s shorted shares with 3.23%. FINRA issued in November SYNH’s total 5.61 million shorted shares. That’s 3.23% down from 5.79M shares. Syneos Health Inc – Class A (NASDAQ:SYNH) has 508,900 shares average volume. It’ll cost 11 days for SYNH to recover its former position. 9.18% is Syneos Health Inc – Class A float short.

Lastly it traded at $51.Since November 10, 2017 it’s 12.82% up thus downtrending. SYNH underperformed the S&P 500 by 28.44%.

Syneos Health, Inc. operates as an integrated biopharmaceutical solutions firm in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America.The firm is valued at $5.25 billion. It operates through two divisions, Clinical Solutions and Commercial Solutions.Currently it has negative earnings. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist clients with drug development process.

For more Syneos Health, Inc. (NASDAQ:SYNH) news announced recently go to:,,, or The titles are as follows: “Syneos Health Wins Society for Clinical Research Sites Eagle Award for Second Consecutive Year” announced on October 15, 2018, “Syneos Health Reports Third Quarter 2018 Results” on November 06, 2018, “Syneos Health to Present at the Jefferies 2018 London Healthcare Conference” with a publish date: November 05, 2018, “Study Reveals Traditional Digital Advertising Rules Don’t Apply in Clinical Trial Recruitment” and the last “Premarket analyst action – healthcare” with publication date: October 19, 2018.

Syneos Health, Inc. (NASDAQ:SYNH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.